Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its First-In-Human (FIH) Phase I trial and development plans for ITI-1001. The FDA addressed the Company’s questions and provided feedback on key components of the planned IND application for the candidate, ITI-1001, for the treatment of newly diagnosed Glioblastoma Multiforme (GBM).
{iframe}https://www.bloomberg.com/press-releases/2020-03-03/immunomic-therapeutics-announces-completion-of-pre-ind-meeting-with-us-fda-for-iti-1001-a-vaccine-for-the-treatment-of-gbm{/iframe}